This study is looking at how well four different medications — vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib — work in treating meningioma that is growing or getting worse. These medicines may stop tumor growth by blocking certain enzymes. To join, you must have a meningioma that has been confirmed by a pathologist and have specific genetic changes (mutations) in your tumor, such as in the SMO, PTCH1, NF2, CDKN2A, AKT1, PIK3CA, or PTEN genes. The study wants to see if these treatments can stop your tumor from growing for at least 6 months and if they can shrink your tumor. This study is currently recruiting 124 participants.

Study design

This is a Phase II interventional study where participants are assigned to one of four treatment arms based on the specific genetic changes in their tumor. It is designed to enroll 124 participants.

What's involved

Participants will take one of the study drugs by mouth daily, with cycles repeating every 28 days. This continues as long as the treatment is working and side effects are manageable.

Compensation

Not stated in the trial record.

Follow-up

The study will measure how long it takes for the disease to progress at 6 months and will assess tumor response for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.